Overview

• Zoetis Q3 2025 revenue of $2.4 bln missed analyst expectations

• Adjusted net income for Q3 2025 grows 9% organically

• Company revises full year 2025 revenue guidance due to broader macro trends

Outlook

• Zoetis revises full-year 2025 revenue guidance to $9.400 bln - $9.475 bln

• Company narrows full-year 2025 adjusted net income growth to 5.5% - 7.0%

• Zoetis maintains adjusted diluted EPS guidance at $6.30 to $6.40

Result Drivers

• U.S. SEGMENT - Revenue decreased 2% on reported basis but increased 3% organically, driven by companion animal products and livestock portfolio growth

• INTERNATIONAL SEGMENT - Revenue increased 3% on reported basis and 6% organically, driven by parasiticides and dermatology products

• REGULATORY MILESTONES - Achieved significant product approvals and geographic expansions, enhancing growth strategy

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Zoetis Inc is $192.00, about 24.8% above its November 3 closing price of $144.35

• The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release: ID:nBw5RwjVxa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)